Cue Biopharma sets 2026 annual meeting, proposal deadlines

Cue Biopharma, Inc. has scheduled its 2026 Annual Meeting of Stockholders for April 13, 2026.

Rhea-AI Filing Summary

Cue Biopharma, Inc. has scheduled its 2026 Annual Meeting of Stockholders for April 13, 2026. The company explains how stockholders can submit proposals or director nominations for that meeting and the deadlines that apply.

Stockholder proposals intended for inclusion in the company’s proxy materials under SEC Rule 14a-8 must be received at Cue Biopharma’s Boston headquarters by February 28, 2026, which the company considers a reasonable time before it begins printing and mailing proxy materials. For other business or director nominations to be brought directly before the meeting under the company’s Amended and Restated Bylaws, notice must also be received by February 28, 2026, or the later of 90 days before the meeting and 10 days after public announcement of the meeting date.

The company notes that stockholders who plan to solicit proxies in favor of their own director nominees, rather than the company’s nominees, and who seek to comply with the SEC’s universal proxy rule (Rule 14a-19), must likewise provide the required notice by February 28, 2026. If a stockholder misses these deadlines, the board’s named proxies may exercise discretionary voting authority on that stockholder’s proposal at the 2026 Annual Meeting.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Cue Biopharma (CUE) holding its 2026 Annual Meeting of Stockholders?

Cue Biopharma has set April 13, 2026 as the date for its 2026 Annual Meeting of Stockholders. This meeting allows shareholders to vote on directors and other matters properly brought before the meeting under the company’s bylaws and SEC proxy rules.

What is the deadline for Cue Biopharma (CUE) stockholder proposals under Rule 14a-8 for the 2026 meeting?

To be included in Cue Biopharma’s proxy statement under SEC Rule 14a-8, stockholder proposals for the 2026 Annual Meeting must be received at the company’s principal executive offices on or before February 28, 2026, which the company treats as a reasonable time before printing proxy materials.

How can Cue Biopharma (CUE) stockholders submit other business or director nominations for the 2026 meeting?

Under Cue Biopharma’s Amended and Restated Bylaws, stockholders must give advance written notice for director nominations or other business. For the 2026 Annual Meeting, this notice must arrive by February 28, 2026, following the company’s advance notice procedure and format requirements.

What happens if a Cue Biopharma (CUE) stockholder misses the February 28, 2026 deadline?

If a stockholder fails to provide notice by February 28, 2026, the persons named as proxies in Cue Biopharma’s proxy materials for the 2026 Annual Meeting may exercise discretionary voting power on that stockholder’s proposal, meaning it may still be voted on without tailored proxy disclosure.

How does SEC Rule 14a-19 (universal proxy) affect Cue Biopharma (CUE) stockholders in 2026?

Stockholders planning to solicit proxies for their own director nominees at Cue Biopharma’s 2026 Annual Meeting must comply with SEC Rule 14a-19. They must provide the detailed notice required by Rule 14a-19 by February 28, 2026, aligning with the meeting’s universal proxy deadlines.

Where must Cue Biopharma (CUE) stockholder proposals for 2026 be delivered?

Proposals and notices for Cue Biopharma’s 2026 Annual Meeting must be delivered to the company’s principal executive offices at 40 Guest Street, Boston, Massachusetts 02135. Delivery by the February 28, 2026 deadline is required for consideration under Rule 14a-8 and the bylaws.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:00 PM EST Learn about SEC filing dates

0001645460false00016454602026-02-182026-02-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 18, 2026

Cue Biopharma, Inc.

(Exact name of Registrant as specified in its charter)

Delaware		001-38327		47-3324577
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

40 Guest Street Boston, Massachusetts		02135 (Zip Code)
(Address of principal executive offices)

(617) 949-2680

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CUE		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

Cue Biopharma, Inc. (the “Company”) has set April 13, 2026 as the date for the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Proposals of stockholders intended to be presented at the 2026 Annual Meeting pursuant to Rule 14a-8 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), must be received by the Company at its principal executive offices a reasonable time before the Company begins to print and send its proxy materials in order to be considered for inclusion in the Company’s proxy statement and proxy card relating to the 2026 Annual Meeting. The Company will consider proposals received on or before February 28, 2026 to have been received a reasonable time before the Company begins to print and send its proxy materials.

In addition, the Company’s Amended and Restated Bylaws (the “Bylaws”) establish an advance notice procedure for nominations for election to the Board of Directors of the Company (the “Board”) and other matters that stockholders wish to present for action at an annual meeting other than those to be included in the Company’s proxy statement. The Company must receive such proposals by the later of the close of business 90 days prior to such annual meeting and 10 days following the day on which notice of the date of such annual meeting was mailed or public announcement of the date of such annual meeting was first made. For the 2026 Annual Meeting, such deadline falls on February 28, 2026. If the stockholder fails to give notice by this date, then the persons named as proxies in the proxies solicited by the Board for the 2026 Annual Meeting may exercise discretionary voting power regarding any such proposal. The Bylaws specify requirements as to the form and content of a stockholder’s notice.

In addition to satisfying the advance notice provisions in the Bylaws relating to director nominations, including the earlier notice deadlines set out above, to comply with Rule 14a‑19, the Securities and Exchange Commission’s universal proxy rule, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees in compliance with Rule 14a-19 under the Exchange Act must also provide notice that sets forth the information required by Rule 14a-19 by the later of 60 days prior to the date of the annual meeting or the 10th day following public announcement by the Company of the date of the annual meeting. For the 2026 Annual Meeting, such deadline falls on February 28, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Cue Biopharma, Inc.
Date: February 18, 2026				By:		/s/ Usman Azam
				Name: Usman Azam
				Title: President and Chief Executive Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 45.3 KB